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Abstract A prognostic interpretation of preneoplastic lesions
would have impact in bronchial carcinoma early diagnosis and
through the study of Erb-B family receptors as they have an
important role in lung carcinogenesis. The existence of drugs
as tyrosine kinase inhibitors stressed the importance of
studying gene alterations for selected chemoprevention
schemes and characterization of carcinogenesis. Bronchial
preneoplastic lesions were characterized by immunohisto-
chemistry using the antibodies LP34 (high weigh molecular
cytokeratin), CK7, chromogranin A, Ki67, p53, C-erbB-2 and
EGFR. HER2 and EGFR gene copy number was also
evaluated by fluorescent in situ hybridization in those
lesions. The expected results defined the origin cell for basal
cell hyperplasia and squamous metaplasia as adaptative
lesions and dysplasia. By known experiences and published
data, beyond the stem cell, the spectral evolution of
bronchial preneoplastic lesions was demonstrated by charac-
terizing basal cells (LP34) and their neoplastic potentiality.
Dysplasias showed a higher expression of EGFR, Ki67 and
p53 with a stepwise increase with the gravity of the
respective grading. C-erbB-2 immunohistochemical over-
expression was a rare event in preneoplastic lesions.
Polysomy was the main mechanism for EGFR and HER2/
neu higher gene copy number and together with increased
proliferation index (Ki67) will account to preview bronchial
carcinogenesis.
Keywords Bronchial squamous metaplasia .
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Introduction
Lung cancer is the leading cause of death by malignancy in
developed countries and throughout the world. Environ-
mental and occupational exposures, such as polyaromatic
hydrocarbons, radon, asbestos, nickel, arsenic and chromi-
um, are important determinants of lung cancer risk, but
cigarette smoking is the main risk factor, accounting for
about 90% of the cases in men, 70% of the cases in women
and within today ex-smokers comprising nearly 50% of all
new lung cancer cases [1–5].
The overall 5-year survival rate for lung cancer patients
remains less than 15% [6], and the death rate for lung
cancer exceeds the combined total for breast, prostate and
colon cancer in developed countries [5]. The major reasons
for the poor prognosis for lung cancer are the lack of
effective screening and early diagnosis procedures, the
propensity for early metastasis and the inability of systemic
therapies to cure patients with widely metastatic disease [7].
Lung cancer is the result of a multi-step accumulation of
genetic and/or epigenetic alterations; therefore, a better
understanding of the molecular mechanism, by which these
alterations affect lung cancer pathogenesis, would provide
new and more effective strategies for chemoprevention,
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early diagnosis and targeted treatment [8]. The existence of
novel drugs against specific molecular targets like EGFR
and HER2/neu genes leads to the importance of defining
their expression as biomarkers in preneoplastic lesions.
The 1999/2004 WHO lung tumour classification recog-
nizes three types of preinvasive lesions: squamous dyspla-
sia and carcinoma in situ (CIS); atypical adenomatous
hyperplasia and diffuse idiopathic pulmonary neuroendo-
crine cell hyperplasia [9]. Respiratory epithelium adaptative
lesions include basal cell hyperplasia, squamous metapla-
sia, followed by dysplasia and CIS, which precede or
accompany microinvasive or invasive carcinoma. Hyper-
plasia and squamous metaplasia are considered reversible
lesions, while dysplasia and CIS are not [10–15].
Squamous metaplasia as a common adaptative lesion of
the bronchial mucosae, especially in smokers, represents a
precursor step in the development of invasive squamous
cell carcinoma, deserving an accurate study to define its
evolutionary potential to lung cancer, in order to be
determined in bronchial biopsies [10, 14, 16, 17].
Several molecular and genetic abnormalities have been
described in lung carcinogenesis, including activation of
proto-oncogenes and loss of tumour suppressor genes and
DNA repair genes. Proto-oncogenes can be activated by point
mutations, amplification, chromosomal rearrangement and
expression of a high gene copy number. [18–20]. Those
genomic and molecular abnormalities are early events in
lung carcinogenesis and can persist in bronchial lesions for
months or years and their persistence or regression have been
correlated with lesions' evolution [15, 21–30]. Molecular
changes are recognized not only in lung cancer, but also in
bronchial epithelium and parenchyma of current and former
smokers without the development of lung cancer [31, 32].
Epidermal growth factor receptor (EGFR; ErbB-1 gene)
and ErbB-2 (HER2/neu) belong to ErbB family, a family of
tyrosine kinase receptor proteins that includes also ErbB-3
(HER-3) and ErbB-4 (HER-4). The ErbB receptors are
composed of three major domains: an extracellular ligand
binding; a transmembranar segment and a cytoplasmic with
tyrosine kinase activity. ErbB receptor function begins upon
ligand binding and is followed by receptor homo (e.g. Erb-1/
Erb-1) or heterodimerization (e.g. Erb-1/Erb-2), activating
the tyrosine kinase domain of the receptor, which becomes
phosphorylated and acts as a docking site for downstream
signalling molecules and cytoplasmic messenger proteins
that then trigger a cascade of cytoplasmic and nuclear
pathways [15].
It has been suggested and supported by experimental
data that aberrant activation of the kinase activity of ErbB
receptors plays an important role in the neoplastic transfor-
mation and progression, prognosis, survival and resistance
to cytotoxic therapies [6, 7, 15, 33–38]. EGFR's high
expression is an early event in preneoplastic lesions, with
an increasing expression from normal mucosae to hyper-
plasia, metaplasia and dysplasia [6, 38–42]. EGFR is
overexpressed in 84% of squamous cell carcinoma, 65%
of adenocarcinomas and 68% of large cell lung carcinomas
[41]. As it seems, that ErbB2 is also highly expressed in
bronchial preneoplastic lesions and its overexpression is
less common in carcinomas (less than 35% of non-small
cell lung carcinomas (NSCLC), mainly adenocarcinomas)
[18, 41, 43]. The heterodimer EGFR/HER2-neu has been
shown to have a stronger proliferative effect than the
corresponding homodimers [38, 44–46]. Amplification and
polysomy of EGFR and HER2-neu and overexpressed
proteins have been related to survival in patients with
NSCLC (non- small cell lung cancer), but contradictory
results have been published [47–51]. New therapies have
also been developed recently directed to these two
molecular targets, some of them being applied in chemo-
prevention trials, stressing the necessity to understand their
expression in adaptative and preneoplastic lesions [5, 52–
56]. This study concerned bronchial preneoplastic lesions
observed in biopsies as basal cell hyperplasia, squamous
metaplasia and dysplasia. Using immunohistochemistry,
those lesions were characterized by antibodies applied
against LP34, CK7, chromogranin A, Ki67, p53, C-erbB-
2 and EGFR. HER2 and EGFR gene copy number was also
evaluated by fluorescent in situ hybridization (FISH), using
normal controls. The aim of the present study is to achieve
a better understanding of the spectral evolution of bronchial
adaptative and preneoplastic lesions, by recognizing the
expression of EGFR and HER2-neu as potential biomarkers
for lung cancer risk assessment. This knowledge would
help to provide new and more effective strategies for
chemoprevention, early diagnosis and targeted treatment.
Materials and methods
Material
A number of 67 bronchial biopsies were included in this study,
comprising 89 preneoplastic lesions, selected from recent data
base, by considering the preservation, number and dimension
of the small fragments obtained by bronchial fibroscopy and
represented 16 basal cell hyperplasia, 40 squamousmetaplasia
and 33 epidermoid dysplasia (7 mild dysplasia, 7 moderate
dysplasia, 4 severe dysplasia and 15 CIS) (Fig. 1a, b, c, d, e);
in 22 cases there was concomitancy of the lesions. The
population consisted of 57 men and 10 women, with
66.3 years as mean age (range 38–92).
Hyperplasia was defined when more than four basal cell
layers were observed. Squamous metaplasia was considered
when there was replacement of ciliated columnar epitheli-
um by pavimentous epithelium without atypia. Dysplasia
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was graded as mild, moderate and severe/CIS according to
the levels of atypia.
Biopsy products were routinely fixed in 4% neutral
buffered formalin immediately after bronchial fibroscopy.
They were processed and embedded in paraffin. One
paraffin block was chosen from each case, containing
several representative fragments. From each paraffin block,
several cuts 5-μm thick sections were made and put on
glass slides then stained with haematoxylin–eosin and
reviewed by two pathologists in order to ensure the optical
criteria for preneoplastic bronchial lesions according to the
1999/2004 histological WHO/IASLC classification of
preinvasive squamous lesions of the bronchi.
Methods
Immunohistochemistry
The imunnohistochemical analysis included seven different
antibodies: CK7 (Monoclonal Mouse Anti-human, OV-TL
12/30, Dako); LP34 (Monoclonal Mouse Anti-human,
Clone LP34, Dako); chromogranin A (Monoclonal Mouse
Fig. 1 Morphology and immunostaining: a Normal bronchial
epithelium, H&E, ×400. b Basal cell hyperplasia, H&E, ×400. c
Squamous metaplasia, H&E, ×400. d Moderate dysplasia, H&E, ×400.
e In situ carcinoma, H&E, ×400. f CK7 expression, normal
bronchial epithelium, ×400. g Basal cell hyperplasia, LP34, ×400.
h Ki67 3+/70%, ×400. i P53 2+/50%, ×400. j EGFR negative, normal
epithelium, ×400 k EGFR, 3+/60%, ×400. l C-erbB-2, 2+, ×1,000
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Anti-human, Clone DAK-A3, Dako); Ki67 (Monoclonal
Mouse Anti-human, Clone MIB-1, Dako); p53 (Monoclo-
nal Mouse Anti-human, Clone DO-7, Dako); C-erbB-2
(Policlonal Mouse Anti-human, Dako) and EGFR (Mono-
clonal Mouse Anti-human, Clone 31G7, Zymed Labora-
tories Inc.). The procedure was performed according to a
standard avidin-biotin-peroxidase complex. Three-
micrometer tissue sections were placed on coated slides
and allowed to dry overnight. After deparaffinization and
rehydration, antigen unmasking was performed using
Module PT (Lab Vision®) for citrate buffer for 25 min
at pH 6, 98°C for chromogranin A, p53, Ki67 and c-erbB-
2 antibodies. Antigen unmasking was performed with
Pronase E, for 10 min at room temperature for CK7, LP34
and EGFR antibodies. Endogenous peroxidase activity
was quenched using 15 min incubation in 3% diluted
hydrogen peroxide (H2O2). For blocking nonspecific
binding, Ultra V Block (Ultra Vision Kit®; TP-015-HL) was
applied to the sections and then they were incubated at room
temperature, with primary antibodies against CK7 at a dilution
of 1/50 for 30 min, LP34 at a dilution of 1/100 for 60 min,
chromogranin A at a dilution of 1/300 for 30 min, p53 at a
dilution of 1/40 for 30 min, Ki67 at a dilution of 1/50 for
30 min, c-erbB-2 at a dilution of 1/40 for 60 min and EGFR at
a dilution of 1/20 for 30 min. After washing with phosphate-
buffered saline, slides were incubated with biotin-labelled
secondary antibody (Lab Vision®) for 15 min. Primary
antibody binding was localized in tissues using peroxidase-
conjugated streptavidin (Lab Vision®) and 3,3-diaminobenzi-
dine tetrahydrochloride was used as the chromogen according
tomanufacturer's instructions. The slides were counterstained
with hematoxylin, dehydrated and mounted.
For each biopsy, external and the intrinsic positive
control were considered: basal cells for LP34 and columnar
ciliated cells for CK7 in normal bronchial epithelium;
carcinoid tumour sections for chromogranin A; sections of
a colonic tubulo-villous adenoma for p53; female breast
ductal carcinoma in situ for C-erbB-2 and sections of lung
adenocarcinoma with intense EGFR IHC positivity. Ki67
was validated by a small cell lung carcinoma.
LP34, CK7 and chromogranin A expression were
classified as negative if there was no expression or mild
focal expression or positive when there was moderate or
intense and diffuse expression. The cut off to classify a
lesion as positive for proliferative marker Ki67 was 10% in
at least two layers of positive nuclei above the epithelial
basal membrane, since it is normal to observe some
proliferative activity mainly in the basal cell layer.
A score established by other authors was applied to Ki67,
p53 and EGFR protein expression: 0-negative; 1-focal
positivity; 2-mild positivity; 3-moderate positivity; 4-intense
positivity. The intensity was multiplied by the percentage of
positive cells, thus defining a 0–200% score as negative or
low expression, 201–300% score as intermediate expression
and a 301–400% score as high expression [19].
The expression of C-erbB-2 was validated by membrane
staining and an identical score to the one used in breast
cancer was applied with some alterations because of the
limited number of cells observed. Each specimen was
scored semi-quantitatively according to the intensity of
membrane immunostaining in a 4-point scale: 0/negative -
absence of staining; + - weak staining and/or no homoge-
neous staining; ++ - moderate homogeneous membrane
staining; +++ - intense homogeneous membrane staining.
For the ++ and +++, we registered the number/percentage
of stained cells. Cytoplasmic staining was not considered
when present.
Fluorescence in situ hybridization (FISH)
Sections of formalin-fixed paraffin-embedded specimens, 4-
μm thick, were incubated at 65°C for 24 h, deparaffinized in
two xylene washes for 10 min and dehydrated in ethanol. The
slides were then incubated at 120°C for 4 min with 10 mM
citrate buffer (ph 6.0), followed by saline sodium citrate buffer
(2×SCC pH 7.0) washes. Sections were digested with
proteinase K (0.25 mg/ml in 2×SCC, Sigma, pH 7.0) for
5 min at 37°C, followed by new 2×SCCwash and post-fixation
with 1% formalin for 10 min at room temperature. The slides
were later on dehydrated in ethanol series (70–90–100%) for
2 min. Dual-colour FISH assays for HER2 were performed by
using Qbiogene HER2/neu (17q21)/Alphasatellite 17 dual
colour probe, and for EGFR, the Vysis, Inc. USA LSI EGFR
Spectrum Orange/CEP 7 Spectrum Green probe was used.
Ten-microliter probe set was applied to the selected area of the
slides and the hybridization areas were covered with a glass
cover slip and sealed with rubber cement. The slides were
incubated at 90°C for 6 min for co-denaturation and at 37°C
for 12–18 h for hybridization in a humidified chamber. Post-
hybridization washes were performed with 50% formamide/
2×SCC (pH 7.0) at 46°C for 5 min, followed by 2×SSC at
46°C for 2 min. After dehydratation in ethanol series, 4′, 6′-
diamidino-2-phenylindole (DAPI; 0.15 mg/ml in Vectashield
mounting medium, Vector Laboratories, Bulingame, CA,
USA) was applied for chromatin counterstaining.
Microscopic analysis was performed on a Nikon Eclipse
80i bright field and epifluorescent microscope equipped
with LUCIA cytogenetics software. Fluorescence signals
were scored using single-band filters for DAPI, FITC,
Texas Red and triple-band pass filter (DAPI, FITC and
Texas Red). Images were recorded with a Nikon digital
DMX 1200 F camera in monochromatic layers, which were
subsequently merged by Nikon ACT-1 capture software.
The reference slide (stained with haematoxylin–eosin)
usually contained normal bronchial epithelium adjacent to
the adaptative and preneoplastic lesions and at least 100 non-
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overlaping interphase nuclei were scored in each fragment for
both HER2 and chromosome17 centromer signals and for
EGFR and chromosome7 centromer signals, following
scoring guidelines and constant adjustments of microscope
focus when signals were located at different levels.
Two independent observers performed analysis in a
blinded study and scored results, restricted to the selected
lesions and bronchial epithelium in each case, with
reproducible results.
Six major FISH patterns were identified: disomy (≤2
gene copies per nucleus in >90% of cells); low trisomy (≤2
gene copies per nucleus in ≥40% of cells, 3 gene copies in
10–40% of cells, ≥4 gene copies in <10% of cells); high
trisomy (≤2 gene copies per nucleus in ≥40% of cells, 3
gene copies in ≥40% of cells, ≥4 gene copies in <10% of
cells); low polysomy (≥4 gene copies per nucleus in 10–
40% of cells); high polysomy (≥4 gene copies per nucleus
in ≥40% of cells) and gene amplification (defined by
presence of tight EGFR gene clusters and a ratio of EGFR
gene to chromosome of ≥2 or ≥15 copies of EGFR per cell
in ≥10% of analysed cells), according to a FISH scoring
System defined by Cappuzzo et al. [57]. Amplification and
high polysomy were considered as FISH-positive results.
Statistical analysis
Comparisons were performed using bilateral chi-squared
tests or Fisher exact test when needed, because of the small
number of lesions in some categories. Anova test was
applied to compare the markers expression's percentage.
Results
Differentiation markers
Basal cell hyperplasia positive LP34 cells in the lower cell
layers revealed clear cut to squamous metaplasia staining
up to the top cell layer, by loss of CK7 expression (Table 1,
Fig. 1f, g). Accordingly, dysplasias showed always LP34
positivity and CK7 negativity.
Chromogranin A expression was negative in all the cases
(Table 1).
Caliciform cell hyperplasia, when present, was negative
for LP34 (only the basal cell layer remained positive) and
maintained the expression for CK7.
Proliferation (Ki67) and apoptotic (p53) markers
Significant differences of Ki67 expression were found
between basal cell hyperplasia and squamous metaplasia
group and dysplasia group cases (p=0.001). Ki67 expression
was higher in dysplasia (p=0.0007). There was also found a
stepwise increment of expression from basal cell hyper-
plasias, to squamous metaplasia and dysplasia (p<0.0001).
The intense expression of Ki67 (intense positive cases) was
shown to have a statistical significant increase from basal
cell hyperplasia, to squamous metaplasia and dysplasia (p=
0.0002). (Tables 2 and 3, Fig. 1h). Intense positive cases were
observed in 19 (57.6%) dysplasias, 9 (22.5%) metaplasias and
one basal cell hyperplasia (6.25%). There were no significant
differences between the three grades of dysplasia. Despite the
intense positive cases observed, moderate expression of Ki67
was the second predominant type of expression in dysplasia
(11 cases, 33.3%). Weak expression of Ki67 was mainly
observed for basal cell hyperplasia (8 cases, 50%) and
squamous metaplasia (13 cases, 32.5%).
An increasing expression for p53 in all the three types of
lesions was observed (p<0.0001). P53 expression was
significantly higher in dysplasia when compared with basal
cell hyperplasias and metaplasias (p=0.0007). Intense
positive cases were also more frequent in dysplasia (p=
0.0001). In 10 basal cell hyperplasias (62.5%) and 22
squamous metaplasias (55%), it was possible to observe a
weak p53 expression. An intense expression of p53 was
observed in 20 cases (60.6%) of dysplasia (Tables 2 and 3,
Fig. 1i).
EGFR and C-erbB-2/HER2 protein and gene expression
EGFR immunohistochemical expression was significantly
higher in dysplasias when compared with other preneo-
LP34 CK7 Chromogranin A
Positive Negative Positive Negative Positive Negative
Basal cell hyperplasia n=16 16 0 0 16 0 16
100% 0% 0% 100% 0% 100%
Squamous Metaplasia n=40 40 0 0 40 0 40
100% 0% 0% 100% 0% 100%
Dysplasia n=33 33 0 0 33 0 33
100% 0% 0% 100% 0% 100%
Table 1 LP34, CK7 and
chromogranin A expression
in preneoplastic lesions
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plastic lesions (p=0.009) (Tables 2 and 3, Fig. 1j, k, Fig. 2).
EGFR IHC expression increased between the three
groups of lesions (p=0.0005). The intensity of the
expression was higher in the group of dysplasia followed
by squamous metaplasia, with 18 (54.5%) dysplasias
showing moderate expression and 3 cases (9.1%) intense
expression, while 14 (35%) squamous metaplasia pre-
sented moderate expression and 1 (2.5%) intense expres-
sion (p=0.005). Basal cell hyperplasia showed mainly a
low EGFR expression, counting ten (62.5%) cases.
Statistical differences between the different grades of
dysplasia were not found (Fig. 2). C-erbB-2 protein
overexpression was clearly observed in only one severe
dysplasia (Tables 2 and 3, Fig. 1l), without statistical
differences between the three groups of lesions or
according to the severity of the dysplasia (p=0.14). C-erbB-2
protein expression was less frequent than EGFR.
EGFR and HER2 gene increased copy number was more
often due to polysomy than to amplification. Among the
four cases with intense EGFR protein expression, three had
high polysomy and one showed disomy.
The number of FISH EGFR positive cases were higher
in the group of dysplasia (p=0.0002) (Fig. 3). Statistical
significant correlation between EGFR IHC expression and
FISH EGFR results was determined when the intensity of
IHQ expression (positive intense vs. non-intense positive
cases) was considered (p=0.0092) (Fig. 4).
HER2 FISH positive cases (n=4) were due to high
polysomy. In one case (n=1), high trisomy was observed.
All high polysomy cases were identified in CIS cases, and
the high trisomy case was identified in a basal cell
hyperplasia. These cases were IHC negative. The IHC-
positive C-erbB-2 case showed low trisomy and was
considered FISH HER2 negative (Fig. 5a, b, c).
Ki 67 p53 C-ErbB-2 EGFR
No. (%) No. (%) No. (%) No. (%)
Basal cell hyperplasia (n=16) Negative 1 6.25 1 6.25 15 93.75 5 31.25
+ 9 56.25 10 62.5 1 6.25 9 43.75
++ 5 31.25 5 31.25 0 0 1 6.25
+++ 1 6.25 0 0 0 0 1 6.25
Squamous metaplasia (n=40) Negative 8 20 5 12.5 39 97.5 6 15
+ 18 45 22 55 0 0 13 32.5
++ 9 22.5 12 30 1 2.5 14 35
+++ 5 12.5 1 2.5 0 0 7 17.5
Dysplasia (n=33) Negative 0 0 1 3 27 81.8 4 12.1
+ 3 9.1 8 24.2 5 15.2 7 21.3
++ 17 55.5 9 27.3 1 3 15 45.5
+++ 13 39.4 15 45.5 0 0 4 12.1
Table 2 Ki67, p53, C-erbB-2
and EGFR intensity of
expression in preneoplastic
lesions
Ki 67 p53 C-ErbB-2 EGFR
No. (%) No. (%) No. (%) No. (%)
Basal cell hyperplasia (n=16) Neg 2 12.5 1 6.25 15 93.75 5 31.25
Low pos 8 50 10 62.5 1 6.25 10 62.5
Mod pos 5 31.25 2 12.5 0 0 1 6.25
Pos int 1 6.25 3 18.75 0 0 0 0
Squamous metaplasia (n=40) Neg 13 32.5 5 12.5 39 97.5 6 15
Low pos 13 32.5 22 55 0 0 19 47.5
Mod pos 5 12.5 4 10 1 2.5 14 35
Pos int 9 22.5 9 22.5 0 0 1 2.5
Dysplasia (n=33) Neg 0 0 1 3 27 81.8 4 12.2
Low pos 3 9.1 8 24.2 5 15.2 8 24.2
Mod pos 11 33.3 4 12.2 1 3 18 54.5
Pos int 19 57.6 20 60.6 0 0 3 9.1
Table 3 Ki67, p53, c-erbB-2
and EGFR expression in pre-
neoplastic lesions considering
intensity and percentage of cells
with expression
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Discussion
As lung carcinogenesis is a multistep process, preneoplastic
or preinvasive bronchial lesions' evolution to bronchial
carcinoma depends upon the molecular and genetic abnor-
malities accumulated in time. Those abnormalities increase
from the normal bronchial epithelium through basal cell
hyperplasia, squamous metaplasia and low-grade to high-
grade dysplasia. Certain proteins and genes play key roles
in lung carcinogenesis and their aberrant expression in that
process makes them as potential biomarkers susceptible to
discriminate a subpopulation of patients with particularly
active mutagenesis, progressive cancerization process and
at very high risk to develop lung cancer [58].
LP34, CK7, chromogranin A, Ki67, p53, EGFR and C-
erbB2 were the seven biomarkers chosen for this study as
their abnormal expression is related with the oncogenic
process. The first three were used successfully as differen-
tiation markers of the preneoplastic lesions.
A basal cell origin for basal hyperplasia, squamous
metaplasia and dysplasia was clearly defined, based on
LP34 and CK7 expression. Immunohistochemical differen-
tiation markers like LP34, CK7 and chromogranin A
demonstrated useful to discriminate preneoplastic lesions
from other proliferative lesions like caliciform cell hyper-
plasia or neuroendocrine cell hyperplasia. As expected,
basal cell hyperplasia and squamous metaplasia are always
LP34-positive and CK7 and chromogranin A-negative,
indicating basal cell origin and conditioning squamous cell
carcinoma as a basal cell carcinoma. In contrast, caliciform
cell hyperplasia maintains cytoplasmic CK7 positivity cells
and inconstant LP34 membrane positivity, reflecting an
origin in cylindrical cells of the upper cell layer of the
respiratory epithelium in bronchial adenocarcinoma carci-
nogenesis. Chromogranin A, a neuroendocrine marker, was
constantly negative in this study, emphasizing that neuro-
endocrine cell hyperplasia has a different cell commitment.
Ki67 expression stepwise increment reflects the increas-
ing proliferative index observed in the spectrum of preneo-
plastic lesions. The statistical higher expression observed in
dysplasia group compared to basal cell hyperplasia and
squamous metaplasia defines two groups of lesions accord-
ing to their proliferative index. As other authors observed,
the intensity of Ki67 expression is also higher in dysplasia.
This way, we reinforce the utility of Ki67 as a biomarker,
namely for dysplasia, as it appears as a group characterized
by high proliferative index, subscribing the literature and
other authors' study of preneoplastic lesions [22–26, 59].
P53, the “guardian” maintaining the integrity of the
genome by participating in the DNA damage checkpoints
in the cell cycle, regulating cellular proliferation and
apoptosis [20], has been detected in preneoplastic lesions
of the lung, suggesting that it occurs early during lung
carcinogenesis [14, 18, 20] as the obtained results con-
firmed. P53 expression was significantly higher in dyspla-
sia when compared with hyperplasia and metaplasia, and
the intensity of expression was also higher in the dysplasia
group, supporting p53 accumulation involvement in the
development of squamous cell lung cancer and fixing p53
as a remarkable biomarker in lung carcinogenesis.
There are many studies concerning EGFR, C-erbB-2,
Ki67 and p53 expression in lung cancer. However, there are
Fig. 2 (MS Excell) Immunohistochemical EGFR expression between
the preneoplastic lesions Fig. 4 (MS Excell) Correlation between immunohistochemical EGFR
expression and FISH results
Fig. 3 (MS Excell) EGFR FISH results according to preneoplastic
lesions
Virchows Arch (2011) 458:571–581 577
fewer results validating these markers in preneoplastic
lesions and most of them used only immunochemistry
techniques. By analysing the expression of those biomarkers,
using not only immunohistochemistry but also feasible
molecular techniques, such as FISH and correlating the
results obtained by the two different techniques, bronchial
preneoplastic lesions achieve prognostic significance.
EGFR immunohistochemical increased expression in
preneoplastic lesions, increasing from basal cell hyperplasia
to dysplasia, had been demonstrated [6, 7, 21, 38–42, 55, 60].
Meert et al. [21] also demonstrated not only an increasing
EGFR rate from normal bronchial epithelium to CIS and
microinvasive tumours, but also a statistically significant cut
off between mild dysplasia and severe dysplasia. Although
the greater expression has been seen in dysplasia, statistical
differences between the different grades of dysplasia were
not demonstrated (probably because the number of cases of
dysplasia was limited).
EGFR high gene copy number was due more frequently
to polysomy than to amplification. FISH-positive EGFR
cases are present in all types of preneoplastic lesions and
were higher in dysplasia group. Polysomy appears as an
early event in the sequence of hyperplasia–metaplasia–
dysplasia. The higher frequency of polysomy in preneo-
plastic lesions is reflected in the high frequency of this
event in squamous cell carcinomas, constituting the earliest
molecular event in lung carcinogenesis [17, 22, 41].
EGFR protein was overexpressed in all lesions with an
increased gene copy number. There was statistical significant
correlation between EGFR immunohistochemical expres-
sion and FISH EGFR results, when considering the intensity
of IHC expression [17]. Therefore, it was demonstrated that
protein expression does reflect high gene copy number, like
polysomy and amplification. Although EGFR gene ampli-
fication is implicated as one mechanism for EGFR over-
expression, it does not seem to be the main one [61].
Despite an increasing expression of EGFR and Ki67
along the spectrum of preneoplastic lesions, no correlation
between the two markers was found. Meert et al. recently
described that low-grade lesions showed no EGFR or Ki67
expression contrasting with high-grade lesions. EGFR
overexpression is associated with cell proliferation, making
EGFR an early marker of malignant transformation in lung
carcinogenesis [21, 38, 59].
C-erbB-2 immunohistochemical overexpression is less
frequent than EGFR overexpression, supporting the minor
role of C-erbB-2 in squamous cell carcinogenesis when
compared with EGFR [17, 62]. In our study, only one case
of severe dysplasia showed C-erbB-2-positive immunohis-
tochemical expression and polysomy was observed in 70%
of the cells. C-erB-2 FISH-positive cases were due to high
polysomy, showing that amplification is less frequent as a
high gene copy number event. No statistical significant
correlation was obtained between C-erbB-2 gene and
protein expression.
C-erB-2 does not seem to be involved in the first steps of
lung carcinogenesis [16]. For Piyathilake et al., the
expression of C-erbB-2 was significantly higher in squa-
mous cell carcinoma and associated precancerous lesions
than in normal epithelium and hyperplastic lesions, but no
stepwise expression of C-erbB-2 was observed, suggesting
its lack of importance in the squamous cell lung carcino-
genesis [38]. HER2/neu increased copy number is observed
in approximately 35% of adenocarcinomas and slightly less
Fig. 5 a Dual-colour FISH assay with EGFR (red) and chromosome
7 (green), balanced polysomy, ×1,000. b Dual-colour FISH assay with
EGFR (red) and chromosome 7 (green), amplification, ×1,000. c
Dual-colour FISH assay with HER2neu (red) and chromosome 17
(green), amplification, ×1,000
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frequently in squamous cell carcinomas [18], assuming
more importance in the development of lung adenocarci-
nomas. The increased copy number of HER2/neu in
NSCLC is most often attributable to chromosome duplica-
tion and polysomy [50], rather than amplification [18].
Although EGFR and Ki67 expression increases from
normal epithelium to preinvasive lesions together, this was
not seen for C-erbB-2. Therefore, any correlation between
EGFR and Ki67 expressions and C-erbB-2 expression was
established, like other studies also registered [21, 41, 63–
66]. Interestingly, other studies revealed that EGFR/HER2/
neu heterodimerization expression is capable to induce a
stronger and more sustained proliferative signal than EGFR
homodimers [60, 62].
The need to accurate detection of the EGFR and HER2/
neu gene copy number and protein overexpression, reflect-
ing their importance as biomarkers in squamous cell
pathogenesis, has become even more important because
despite recent advances in lung cancer treatments, improve-
ment in survival has only been modest, showing that
effective therapeutic and early detection approaches are still
lacking [38]. Selection of patients with preneoplastic
lesions expressing selected biomarkers is the way to
provide new and more effective strategies for early
diagnosis, a posterior closer follow-up and eventually
chemoprevention and targeted treatment with better safety
profiles. A variety of new approaches that target selected
biomarkers in lung carcinogenesis are in clinical develop-
ment or have already been approved for second and third
line lung cancer treatment [5, 52–56, 67].
Our comparison between gene copy number and protein
expression contributes to define which are the most reliable
methods to be used in patient selection. Since our study
includes a large number of preneoplastic lesions in a
different population analysed by two different techniques
(IHC and FISH), the results obtained reinforce other results
published before, some of them centred only in one
molecular marker and/or have used a single technique,
which measures either the protein level or the gene
expression. By identifying dysplasia as a group of preneo-
plastic lesions, chemoprevention targeted schemes can be
delineated to select individual patients, considering protein
expression, gene copy number and gene mutational status
with repercussions in drug sensitivity.
Conclusions
We conclude that squamous cell carcinoma preneoplastic
lesions studied have a basal cell origin, as demonstrated by
the unbalance between LP34 and CK7. The differentiation
markers, LP34, CK7 and chromogranin A, successfully
discriminate preneoplastic lesions origin.
Dysplasias showed a higher expression of EGFR, Ki67 and
p53 with a stepwise expression with the gravity of the
preneoplastic lesions, reflecting their importance as potential
biomarkers of preinvasive lesions of the bronchial epithelium
and may be used to identify patients with a higher risk of
developing squamous cell lung carcinoma. C-erbB-2 immu-
nohistochemical overexpression is a rare event in bronchial
preneoplastic lesions, emphasizing the minor role of C-erbB-2
as a biomarker in squamous cell carcinogenesis.
EGFR and HER2/neu high gene copy number was
present in preneoplastic lesions, with a higher EGFR gene
copy number in dysplasias. EGFR and HER2/neu high gene
copy number was due to polysomy more often than to
amplification, reinforcing that amplification is not the main
mechanism for protein overexpression. Although HER2/neu
does not seem to be involved in the early steps of squamous
cell lung carcinogenesis, HER2/neu gene copy number is
important because this gene is a HER family member and
an important heterodimerizarion partner for EGFR.
Biological/genetic markers associated with several mo-
lecular and genetic abnormalities, such as Ki67, p53, EGFR
and HER2/neu, need to be validated as potential and useful
preneoplastic bronchial lesion biomarkers. Risk assessment
should be based not only on smoking consumption and on
histopathology of bronchial lesions, but also on the basis of
in situ molecular biomarkers [58]. Therefore, in the future,
the recognition of those biomarkers will allow a targeted
screening and a posterior closer follow-up to select patients
for chemoprevention schemes and will have a positive
impact on survival.
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